A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Sponsor: Recursion Pharmaceuticals Inc.

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06005974

Patient View

This Phase 2, open-label study evaluates the safety, efficacy, and pharmacokinetics of REC-4881 (12 mg PO daily) in 60 participants with unresectable, locally advanced, or metastatic solid tumors with AXIN1 or APC mutations. Eligible participants are 55+, with progressive disease and ECOG ≤ 1. Excludes recent MEK inhibitor use and LVEF <50%.

Patient Parameters

Program Overview

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.

Description

Approximately 60 individuals will be enrolled in this open-label Phase 2 study, allocated 1:1 between the 2 cohorts - AXIN1 mutation or APC mutation. The purpose of the study is to investigate the safety, efficacy, and pharmacokinetics of REC-4881 for the treatment of participants with unresectable locally advanced or metastatic solid tumors with either mutation. Participants will receive treatment with REC-4881 (12mg PO daily) for up to 2 years.

Eligibility Criteria

Inclusion Criteria

  1. 55 years of age or older with histologically-confirmed unresectable, locally advanced, or metastatic solid tumor with AXIN1 or APC mutation. If a participant has colorectal cancer, then they must be RAS / RAF wild type to enroll into the APC mutant cohort
  2. Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment, or in the opinion of the Investigator have been considered ineligible for standard therapy
  3. Measurable disease at baseline per RECIST 1.1 criteria
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion Criteria

  1. Received treatment with another mitogen-activated protein kinase (MEK) inhibitor within two months of first dose of REC-4881
  2. Left ventricular ejection fraction (LVEF) <50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan

Get This Program In Your Inbox

You can sign up and apply your patients for this program.